Atea Pharmaceuticals Stock Today

AVIR -  USA Stock  

USD 24.74  0.37  1.47%

Atea Pharmaceuticals is selling at 24.74 as of the 26th of July 2021; that is -1.47 percent decrease since the beginning of the trading day. The stock's lowest day price was 24.17. Atea Pharmaceuticals has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Atea Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of April 2021 and ending today, the 26th of July 2021. Click here to learn more.
 Market Performance
0 of 100
  Odds Of Distress
Over 72

Atea Pharmaceuticals Stock Profile

The upcoming quarterly report is expected on the 12th of August 2021. Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts. Atea Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs people. more on Atea Pharmaceuticals
Atea Pharmaceuticals generates negative expected return over the last 90 days
Atea Pharmaceuticals has high historical volatility and very poor performance
Atea Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 48.63 M. Net Loss for the year was (10.95 M) with profit before overhead, payroll, taxes, and interest of 33.65 M.
Atea Pharmaceuticals has a poor financial position based on the latest SEC disclosures
About 58.0% of the company shares are held by institutions such as insurance companies
Latest headline from COVID-19 drug developer Adagio plans IPO to cap fast rise - BioPharma Dive
Atea Pharmaceuticals Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Atea Pharmaceuticals SEC Filings
Atea Pharmaceuticals SEC Filings Security & Exchange Commission EDGAR Reports
Legal NameAtea Pharmaceuticals
President CEO, DirectorJoseph Patti  (View All)
Average Analyst Recommendation
Analysts covering Atea Pharmaceuticals report their recommendations after researching Atea Pharmaceuticals' financial statements, talking to executives and customers, or listening in on Atea Pharmaceuticals' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Atea Pharmaceuticals. The Atea Pharmaceuticals consensus assessment is calculated by taking the average forecast from all of the analysts covering Atea Pharmaceuticals.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Atea Pharmaceuticals based on its profitability, leverage, liquidity, source of funds, and operating efficiency. it is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Atea Pharmaceuticals financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 4 - PoorDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares19.4 M21.6 M
Moderately Down
Slightly volatile
Weighted Average Shares Diluted19.4 M21.6 M
Moderately Down
Slightly volatile
Net Cash Flow from Operations320.2 M296.7 M
Significantly Up
Slightly volatile
Total Assets931.8 M863.6 M
Significantly Up
Slightly volatile
Total Liabilities340.8 M315.8 M
Significantly Up
Slightly volatile
Current Assets931.6 M863.5 M
Significantly Up
Slightly volatile
Current Liabilities340.7 M315.8 M
Significantly Up
Slightly volatile
Gross Margin0.890.9
Fairly Down
Slightly volatile
Asset Turnover0.09840.099
Slightly Down
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Atea Pharmaceuticals' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong SellUndervalued
Atea Pharmaceuticals (AVIR) is traded on NASDAQ Exchange in USA. It is located in 2500 Northwinds Parkway Suite 100, Alpharetta, GA 30009, United States and employs 39 people. Atea Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with current market capitalization of 2.07 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Atea Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Atea Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Atea Pharmaceuticals conducts business under null sector and is part of null industry. The entity has 82.74 M outstanding shares of which 4.25 M shares are presently shorted by private and institutional investors with about 11.26 trading days to cover. Atea Pharmaceuticals currently holds about 850.12 M in cash with 296.73 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.27.
Check Atea Pharmaceuticals Probability Of Bankruptcy
Atea Pharmaceuticals holds a total of eighty-two million seven hundred fourty thousand outstanding shares. Over half of Atea Pharmaceuticals outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulation than regular investors in Atea Pharmaceuticals. Please watch out for any change in the institutional holdings of Atea Pharmaceuticals as this could mean something significant has changed or about to change at the company. Please note that no matter how much assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Ownership Allocation (%)

Check Atea Pharmaceuticals Ownership Details

Atea Pharmaceuticals Stock Price Odds Analysis

What are Atea Pharmaceuticals' target price odds to finish over the current price? In regard to a normal probability distribution, the odds of Atea Pharmaceuticals jumping above the current price in 90 days from now is about 42.27%. The Atea Pharmaceuticals probability density function shows the probability of Atea Pharmaceuticals stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Atea Pharmaceuticals has a beta of 0.0455. This suggests as returns on the market go up, Atea Pharmaceuticals average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Atea Pharmaceuticals will be expected to be much smaller as well. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Atea Pharmaceuticals is significantly underperforming DOW.
 Odds Down 24.74HorizonTargetOdds Up 24.74 
57.62%90 days
Based on a normal probability distribution, the odds of Atea Pharmaceuticals to move above the current price in 90 days from now is about 42.27 (This Atea Pharmaceuticals probability density function shows the probability of Atea Pharmaceuticals Stock to fall within a particular range of prices over 90 days) .

Atea Pharmaceuticals Historical Income Statement

Atea Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting Atea Pharmaceuticals's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Atea Pharmaceuticals revenue and expense. Atea Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
As of 07/26/2021, Direct Expenses is likely to grow to about 1.4 M View More Fundamentals

Atea Pharmaceuticals Stock Against Markets

Picking the right benchmark for Atea Pharmaceuticals stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Atea Pharmaceuticals stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Atea Pharmaceuticals is critical whether you are bullish or bearish towards Atea Pharmaceuticals at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Atea Pharmaceuticals without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Equity Search Now


Equity Search

Search for activelly traded equities including funds and ETFs from over 30 global markets
All  Next Launch Module

Atea Pharmaceuticals Corporate Directors

Atea Pharmaceuticals corporate directors refer to members of an Atea Pharmaceuticals board of directors. The board of directors generally takes responsibility for the Atea Pharmaceuticals' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Atea Pharmaceuticals' board members must vote for the resolution. The Atea Pharmaceuticals board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
John Richard - Independent DirectorProfile
Anne VanLent - Independent DirectorProfile
Michael Dunne - Independent DirectorProfile
Armando Anido - Independent DirectorProfile
Please continue to Trending Equities. Note that the Atea Pharmaceuticals information on this page should be used as a complementary analysis to other Atea Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Complementary Tools for Atea Pharmaceuticals Stock analysis

When running Atea Pharmaceuticals price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Money Managers
Screen money managers from public funds and ETFs managed around the world
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Transaction History
View history of all your transactions and understand their impact on performance
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
The market value of Atea Pharmaceuticals is measured differently than its book value, which is the value of Atea Pharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Atea Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Atea Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atea Pharmaceuticals' market value can be influenced by many factors that don't directly affect Atea Pharmaceuticals underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atea Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Atea Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atea Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.